{"nctId":"NCT00754741","briefTitle":"Multi-arm Intervention Diabetes Adherence Study","startDateStruct":{"date":"2008-07"},"conditions":["Diabetes"],"count":1692,"armGroups":[{"label":"Usual care","type":"NO_INTERVENTION","interventionNames":[]},{"label":"Adherence","type":"ACTIVE_COMPARATOR","interventionNames":["Behavioral: Adherence information"]},{"label":"Adherence Plus","type":"ACTIVE_COMPARATOR","interventionNames":["Behavioral: Adherence information plus motivational interviewing"]}],"interventions":[{"name":"Adherence information","otherNames":[]},{"name":"Adherence information plus motivational interviewing","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 2 dispensings for oral medications used to treat diabetes and dyslipidemia in the last 18 month.\n* At least one laboratory result for both glycated hemoglobin and LDL-cholesterol in the last 6 months.\n* Average HbA1c ≥ 7% OR an average LDL ≥ 100 mg/d\n* Continuous health plan enrollment currently and in the previous calendar year with no more than a 1 month lapse of coverage, and benefits that include both medical and pharmacy coverage.\n\nExclusion Criteria:\n\n* Patients who have been institutionalized in a nursing home or in a long-term care facility for more than 3 months in the preceding 18 month period.\n* Participation in a disease management program","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Glycated Hemoglobin Levels","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.88","spread":"1.53"},{"groupId":"OG001","value":"7.91","spread":"1.53"},{"groupId":"OG002","value":"7.79","spread":"1.34"}]}]}]},{"type":"PRIMARY","title":"LDL-cholesterol Levels","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.02","spread":"32.11"},{"groupId":"OG001","value":"87.27","spread":"35.67"},{"groupId":"OG002","value":"85.56","spread":"32.86"}]}]}]},{"type":"SECONDARY","title":"Adherence to Oral Anti-diabetic Medications","description":"Adherence is the estimated proportion of the prescribed dose taken over a 3-month period. Therefore, each estimate of medication adherence represented a 3-month window of use prior to and including the endpoint time (e.g., the adherence estimate at \"6 months post randomization\" represented use beginning at 3 months post-randomization and ending at 6 months post-randomization). Pharmacy claims data (i.e., days supply and refill frequency) were used to estimate adherence at each endpoint date.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"0.35"},{"groupId":"OG001","value":"0.74","spread":"0.36"},{"groupId":"OG002","value":"0.74","spread":"0.37"}]}]}]},{"type":"SECONDARY","title":"Adherence to Lipid-lowering Drugs","description":"Adherence is the estimated proportion of the prescribed dose taken over a 3-month period. Therefore, each estimate of medication adherence represented a 3-month window of use prior to and including the endpoint time (e.g., the adherence estimate at \"6 months post randomization\" represented use beginning at 3 months post-randomization and ending at 6 months post-randomization). Pharmacy claims data (i.e., days supply and refill frequency) were used to estimate adherence at each endpoint date.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"0.37"},{"groupId":"OG001","value":"0.69","spread":"0.36"},{"groupId":"OG002","value":"0.69","spread":"0.36"}]}]}]},{"type":"SECONDARY","title":"Cardiovascular Morbidity and Mortality (Exploratory)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"80","spread":null},{"groupId":"OG002","value":"58","spread":null}]}]}]},{"type":"SECONDARY","title":"Glycated Hemoglobin Levels","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.81","spread":"1.42"},{"groupId":"OG001","value":"7.90","spread":"1.44"},{"groupId":"OG002","value":"7.81","spread":"1.41"}]}]}]},{"type":"SECONDARY","title":"LDL Cholesterol Levels","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.92","spread":"32.33"},{"groupId":"OG001","value":"92.07","spread":"36.68"},{"groupId":"OG002","value":"91.23","spread":"31.17"}]}]}]},{"type":"SECONDARY","title":"Glycated Hemoglobin Levels","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.94","spread":"1.60"},{"groupId":"OG001","value":"7.96","spread":"1.54"},{"groupId":"OG002","value":"7.84","spread":"1.40"}]}]}]},{"type":"SECONDARY","title":"LDL Cholesterol Levels","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.63","spread":"32.41"},{"groupId":"OG001","value":"90.70","spread":"36.90"},{"groupId":"OG002","value":"87.43","spread":"32.43"}]}]}]},{"type":"SECONDARY","title":"Adherence to Oral Anti-diabetic Medications","description":"Adherence is the estimated proportion of the prescribed dose taken over a 3-month period. Therefore, each estimate of medication adherence represented a 3-month window of use prior to and including the endpoint time (e.g., the adherence estimate at \"12 months post randomization\" represented use beginning at 9 months post-randomization and ending at 12 months post-randomization). Pharmacy claims data (i.e., days supply and refill frequency) were used to estimate adherence at each endpoint date.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"0.35"},{"groupId":"OG001","value":"0.74","spread":"0.36"},{"groupId":"OG002","value":"0.74","spread":"0.38"}]}]}]},{"type":"SECONDARY","title":"Adherence to Oral Anti-diabetic Medications","description":"Adherence is the estimated proportion of the prescribed dose taken over a 3-month period. Therefore, each estimate of medication adherence represented a 3-month window of use prior to and including the endpoint time (e.g., the adherence estimate at \"18 months post randomization\" represented use beginning at 15 months post-randomization and ending at 18 months post-randomization). Pharmacy claims data (i.e., days supply and refill frequency) were used to estimate adherence at each endpoint date.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"0.36"},{"groupId":"OG001","value":"0.73","spread":"0.37"},{"groupId":"OG002","value":"0.73","spread":"0.38"}]}]}]},{"type":"SECONDARY","title":"Adherence to Lipid-lowering Drugs","description":"Adherence is the estimated proportion of the prescribed dose taken over a 3-month period. Therefore, each estimate of medication adherence represented a 3-month window of use prior to and including the endpoint time (e.g., the adherence estimate at \"12 months post randomization\" represented use beginning at 9 months post-randomization and ending at 12 months post-randomization). Pharmacy claims data (i.e., days supply and refill frequency) were used to estimate adherence at each endpoint date.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"0.36"},{"groupId":"OG001","value":"0.69","spread":"0.37"},{"groupId":"OG002","value":"0.69","spread":"0.37"}]}]}]},{"type":"SECONDARY","title":"Adherence to Lipid-lowering Drugs","description":"Adherence is the estimated proportion of the prescribed dose taken over a 3-month period. Therefore, each estimate of medication adherence represented a 3-month window of use prior to and including the endpoint time (e.g., the adherence estimate at \"18 months post randomization\" represented use beginning at 15 months post-randomization and ending at 18 months post-randomization). Pharmacy claims data (i.e., days supply and refill frequency) were used to estimate adherence at each endpoint date.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"0.37"},{"groupId":"OG001","value":"0.70","spread":"0.37"},{"groupId":"OG002","value":"0.70","spread":"0.37"}]}]}]},{"type":"SECONDARY","title":"Cardiovascular Morbidity and Mortality (Exploratory)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"112","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":567},"commonTop":[]}}}